Lupin Launches Biosimilar Ranibizumab Through Sandoz in Europe Except Germany

Lupin launches biosimilar Ranibizumab through Sandoz in Europe except Germany

Ranluspec approved by European Commission in vial and pre-filled syringe forms for retinal disease treatment

Sandoz expands European retinal disease treatment portfolio with launch of Ranluspec biosimilar

Developed by Lupin and approved by the European Commission in February 2026, the ranibizumab biosimilar is being commercialised by Sandoz across the EU excluding Germany. IN BRIEFKEY TAKEAWAYSFAQs Sandoz has announced the European launch of Ranluspec® (ranibizumab), a biosimilar developed, … Read the full press release →

Lupin launches biosimilar Ranibizumab in European market

Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A.